September 13, 2012 11:33 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Piper Jaffray reduced its rating on Corcept Therapeutics (NASDAQ: CORT) from Overweight to Neutral and lowered its price target from $5 to $3. Piper Jaffray said, "We are downgrading CORT to Neutral from Overweight and cutting our price target to $3 from $5 following a series of conversations with endocrinologists, many of whom were investigators. Our Korlym peak sales estimates are now well below the Street as we model not only a slow ramp but also a smaller market opportunity. Our conversations gave us a better understanding of the barriers to adoption for Korlym. In particular, we note the burden placed on prescribers and patients in managing Korlym's extensive drug interactions and risk for hypokalemia."Corcept Therapeutics closed at $2.81 on Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.